fulvestrant has been researched along with azd 6244 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berset, C; Hasler-Strub, U; Hawle, H; Mamot, C; Mueller, A; Neven, P; Perey, L; Rochlitz, C; Rondeau, S; Rudolf, CB; Wiliders, H; Winterhalder, R; Zaman, K | 1 |
| Besser, AH; Brafford, P; El-Ashry, D; Gao, W; Gu, M; Hew, KE; Ince, TA; Lu, Y; Miller, PC; Mills, GB; Simpkins, F; Slingerland, JM; Sun, J; Wei, Z; Zhang, G | 1 |
| Adams, DJ; Boland, GM; Cichowski, K; Crawford, L; Flaherty, KT; Frederick, DT; Herlyn, M; Krepler, C; Liberti, MV; Liu, X; Locasale, JW; Maertens, O; Magpusao, AN; Manchester, HE; McCall, SJ; Mukherjee, S; Singleton, KR; Sproesser, K; Stein, EM; Tingley, JP; Tsui, E; Wood, KC | 1 |
1 trial(s) available for fulvestrant and azd 6244
| Article | Year |
|---|---|
Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Disease Progression; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Middle Aged; Placebos; Postmenopause; Protein Kinase Inhibitors | 2015 |
2 other study(ies) available for fulvestrant and azd 6244
| Article | Year |
|---|---|
MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; MAP Kinase Signaling System; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinases; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Receptors, Estrogen; Transcriptome; Treatment Outcome; Xenograft Model Antitumor Assays | 2016 |
Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence.
Topics: Antineoplastic Agents, Hormonal; Benzimidazoles; Cell Line, Tumor; Estradiol; Evolution, Molecular; Female; Fulvestrant; Humans; Imidazoles; Indoles; Male; Melanoma; Oximes; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-myc; Pyridones; Pyrimidinones; Quinolines; Signal Transduction; Sulfonamides | 2017 |